COPD: balancing oxidants and antioxidants

Bernard M Fischer1,*, Judith A Voynow2,*, Andrew J Ghio3,*

1Department of Pediatrics, Duke University Medical Center, Durham, NC, USA; 2Department of Pediatrics, Children’s Hospital of Richmond at Virginia Commonwealth University, Richmond, VA, USA; 3National Health and Environmental Effects Research Laboratory, US Environmental Protection Agency, Chapel Hill, NC, USA

*These authors contributed equally to this work

Abstract: Chronic obstructive pulmonary disease (COPD) is one of the most common chronic illnesses in the world. The disease encompasses emphysema, chronic bronchitis, and small airway obstruction and can be caused by environmental exposures, primarily cigarette smoking. Since only a small subset of smokers develop COPD, it is believed that host factors interact with the environment to increase the propensity to develop disease. The major pathogenic factors causing disease include infection and inflammation, protease and antiprotease imbalance, and oxidative stress overwhelming antioxidant defenses. In this review, we will discuss the major environmental and host sources for oxidative stress; discuss how oxidative stress regulates chronic bronchitis; review the latest information on genetic predisposition to COPD, specifically focusing on oxidant/antioxidant imbalance; and review future antioxidant therapeutic options for COPD. The complexity of COPD will necessitate a multi-target therapeutic approach. It is likely that antioxidant supplementation and dietary antioxidants will have a place in these future combination therapies.

Keywords: cigarette smoking, mucins, gene regulation, Chinese herbs, acupuncture, dietary antioxidants

Introduction

Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible;1 it can include some combination of emphysema, chronic bronchitis (CB), and small airway obstruction.2,3 The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lungs. The mechanistic basis underlying COPD is complex and can involve recurrent inflammation, oxidative stress (ie, oxidant/antioxidant imbalance), protease/antiprotease imbalance, environmental insult, and host genetics.4 Cigarette smoking serves as the major risk factor for developing COPD and is also the major source of oxidants/reactive oxygen species (ROS) to the lungs and the body in exposed individuals. It is this recurrent oxidative stress from environmental sources (eg, cigarette smoking) and persistent inflammation that can lead to extensive tissue damage and disease exacerbation susceptibility. This review focuses first on the relationship of cigarette smoking to COPD-associated oxidative stress. The second part addresses oxidant regulation of mucin gene expression and also genetic and epigenetic factors important for COPD-associated oxidative stress. Finally, we present an update about the current antioxidant nutritional and dietary supplements that have been evaluated for COPD therapy, along with alternative therapies such...
as acupuncture that have also been evaluated as potential COPD therapeutics.

Cigarette smoking and oxidative stress

Temperatures in the combustion zone of a burning cigarette (800°C–950°C) result in a complete pyrolysis of tobacco. However, immediately downstream, a rapid drop in temperature (200°C–600°C) and a lack of oxygen allow for an incomplete combustion. Subsequently, a complex aerosol is generated during smoking, which includes condensed liquid droplets (the particulate fraction or tar) suspended in a mixture of volatile/semivolatile compounds and combustion gases (the gas fraction). A single puff of such cigarette smoke was quantified to contain $10^{17}$ free radicals in the tar phase and $10^{15}$ in the gas phase.\(^5\) Numerous oxidant compounds have been identified among the 4,000 to 7,000 constituents in cigarette smoke.\(^7\) In the particulate fraction, phenols and semiquinones are recognized among these compounds, while superoxide (O\(_2^–\)), epoxides, peroxides, nitric oxide (NO; 500 to 1,000 ppm), nitrogen dioxide, peroxynitrite (ONOO\(^–\)), and peroxynitrates are included in the gas phase.

Smoking produces a shift in the normal balance between oxidants and antioxidants to impact an oxidative stress both in the lungs and systemically. Oxidants included in cigarette smoke can directly injure cells and tissues, inactivate defense mechanisms, and initiate inflammation, which further elevates oxidative stress. It is difficult, if not impossible, to determine if the oxidants responsible for the stress are those originally included in cigarette smoke or those which result from the associated inflammatory response.

Specific endpoints of oxidative stress which have been quantified with smoking are numerous and diverse and have included: 1) generation of O\(_2^–\), hydrogen peroxide (H\(_2\)O\(_2\)), and nitrite/nitrate; 2) levels of superoxide dismutase, catalase, myeloperoxidase, and cytochrome P450 (and their activities); 3) exhaled breath ethane/alkanes, thiobarbituric acid-reactive substances, and other indices of lipid peroxidation; 4) concentrations of oxidized proteins; 5) total, reduced, and oxidized glutathione; 6) activity of glutathione peroxidase, glutathione transferase, and glutathione reductase; 7) concentrations of prostanooids (F2-isoprostanes and prostaglandin F2-alpha), hydroxyeicosatetraenoic acid products, F(4)-neuroprostanes, 7-ketocholesterol, 24- and 27-hydroxycholesterol, low density lipoproteins, and other cholesterol oxidation products; 8) concentrations of uric acid and allantoin; 9) evidence of DNA damage (8-hydroxy-2′-deoxyguanosine and 8-oxo-2′-deoxyguanosine); 10) histopathology (eg, 4-hydroxy-2-nonenal and 8-hydroxydeoxyguanosine); 11) immunohistochemistry for specific proteins such as nitrotyrosine; 12) gene expression microarray analysis; 13) Trolox equivalent antioxidant capacity; 14) antioxidant reducing capacity; and 15) total radical trapping parameters. These measurements have been obtained in numerous different samples, including cells and their fractions, whole blood, serum, plasma, cord blood, sputum, exhaled breath, breath condensate, lavage fluid, lavage cells, urine, and tissues (eg, lung, vasculature, brain, muscle, testicles, and pancreas).

Oxidant generation with cigarette smoke exposure

Oxidants, including H\(_2\)O\(_2\), can be directly measured in the particulate fraction of cigarette smoke.\(^9\) Metals are also included in the particulate fraction of cigarette smoke, but concentrations appear to be low.\(^16\) There is little evidence to support the assertion that iron and copper, introduced into the body by smoking, catalyze Fenton-type reactions in either the lung or any tissue.

Phagocytes (eg, macrophages and neutrophils) in smokers are elevated in number, both in the lung and systemically, and generate ROS at increased rates.\(^11\) The major cell sources of O\(_2^–\) are likely the nicotine adenine disphosphonucleotide (NADPH) oxidoreductases, but others may also be increased (eg, xanthine oxidase).\(^12\) Catalase, the enzyme responsible for the breakdown of H\(_2\)O\(_2\), is downregulated in ex-smokers.\(^13\) In vitro studies confirm that phagocytes collected from cigarette smokers spontaneously release increased amounts of oxidants such as O\(_2^–\) and H\(_2\)O\(_2\) compared to those from nonsmokers.\(^14\) H\(_2\)O\(_2\) is elevated in bronchoalveolar lavage fluid and in exhaled breath condensate collected from cigarette smokers,\(^15\) and some portion of this was demonstrated to be attributable to the elevated number of macrophages in the lower respiratory tract of smokers and their increased release of O\(_2^–\).\(^16\)

Cigarette smoking is associated with lipid peroxidation and conversion of polyunsaturated fatty acids to hydroperoxides, endoperoxides, aldehydes (eg, malondialdehyde), and alkanes (eg, ethane and pentane). Levels of these end products are increased in smokers, including thiobarbituric acid-reactive products (in sputum, blood, and lung components), isoprostanes (in blood, urine, and breath condensate), 4-hydroxy-2-nonenal adducts, and breath alkanes.\(^17,18\)

Cigarette smoking depletes antioxidants.\(^19\) Concentrations of ascorbate and vitamin E are decreased among smokers.\(^20\)
Smokers have 15%–20% lower serum concentrations of ascorbate than do nonsmokers. These specific changes in ascorbate and vitamin E correspond to an elevated oxidative stress rather than a dietary intake. Values normalize after smoking cessation. Glutathione metabolism appears to be particularly provoked by smoking. Despite glutathione being acutely depleted in cells and in smokers, levels of reduced glutathione are elevated in bronchoalveolar lavage fluid of chronic smokers. It has been proposed that such an increase of lung glutathione in smokers may be an attempt, albeit insufficient, to counter excess oxidant production after cigarette smoke exposure. Exogenous antioxidants appear to have a capacity to prevent some portion of the biological effect and injury following smoking. Pretreatment with antioxidants can decrease lipid peroxidation following exposure to cigarette smoke. There are studies which suggest that vitamins C and E diminish production of oxidants by inflammatory cells and improve pulmonary function in smokers. Supplementation with N-acetylcysteine (NAC) also diminishes in vitro cytotoxicity after cigarette smoke exposure.

Cigarette smoke is also a source of reactive nitrogen species and causes nitrosative stress. Nitric oxide, abundant in cigarette smoke and generated by inflammatory cells, has potent antioxidant and anti-inflammatory actions, but also contributes to oxidative reactions. NO reacts with thiols to produce nitrosothiols associated with biological effects. Nitrosothiol levels have been shown to be higher in breath condensate collected from smokers compared with subjects who do not smoke. NO in cigarette smoke can react with O2 to form peroxynitrite, which decreases antioxidant capacity and augments oxidative stress. NO and peroxynitrite can cause the nitration of tyrosine to form nitrotyrosine products of proteins measurable in body fluids and tissues. However, it must be pointed out that NO levels in smokers were also reported to be normal or even lower relative to nonsmokers. Fractional exhaled nitric oxide was reported to be decreased in smokers. Such reduced NO production was postulated to possibly elevate oxidative stress since this molecule can function as an antioxidant as well as being a prooxidant.

In addition to an elevated oxidant burden in the lung, there is increased systemic oxidative stress in smokers. Plasma Trolox equivalent antioxidant capacity and total glutathione are decreased in cigarette smokers. Peripheral blood neutrophils from smokers release more oxidants than those isolated from normal subjects. The proposal that oxidants in cigarette smoke, whether in the particulate or gas phase, pass through the pulmonary alveolar wall into the blood to induce a disseminated systemic oxidative stress is improbable, as such radicals would rapidly react with molecules in the lung.

### Oxidative stress and disease after cigarette smoke exposure

Oxidative stress resulting from an imbalance between oxidants and antioxidants is proposed as the basis for COPD following exposure to cigarette smoking. Cigarette smoke increases the burden of oxidants in the respiratory tract, either directly included in the cigarette smoke or generated by inflammatory cells, depleting antioxidant defenses and injuring lung cells. Evidence of a relationship between oxidative stress and injury exists. Cell lysis and epithelial permeability are increased after exposure to cigarette smoke, and these effects can be inhibited by antioxidants (ie, glutathione). In addition, there are increased numbers of activated inflammatory cells in the lungs of patients with COPD relative to healthy subjects, and these cells release greater quantities of O2 and H2O2. Importantly, a correlation has been demonstrated between O2 release by peripheral white blood cells and bronchial hyperreactivity in patients with COPD, supporting a role for such oxidants in lung disease after smoking. As discussed later in this article, oxidants have been demonstrated to mediate mucous hypersecretion and impaired mucociliary clearance, which can contribute to injury in COPD. Furthermore, nitrogen-based free radicals also participate in COPD and 3-nitrotyrosine, formed by nitration of tyrosine, is observed in greater concentrations in the lungs of those with COPD.

There is systemic disease after exposure to cigarette smoke. Regarding vascular disease, cigarette smoking is associated with an oxidation of low-density lipoproteins and their deposition in the vasculature with its resultant dysfunction. A depletion of antioxidants has also been documented in atherosclerosis.

Cigarette smoke-induced oxidative stress is postulated to initiate a series of cellular and molecular reactions, which include activation of kinase cascades and transcription factors, release of inflammatory mediators, initiation of inflammation, and cell injury and apoptosis (Figure 1). Consequently, oxidative stress is the initiating factor in the pathway by which cigarette smoke exposure leads to disease. Key among the redox-sensitive transcription factors coordinating the inflammatory response to cigarette smoke are nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) (pro-oxidative) and nuclear factor erythroid 2-related factor 2 (Nrf2; antioxidative). The activation of these transcription
Factors involved in the cascade of events underlying the biological effects of cigarette smoking include oxidative stress, cell signaling pathways, transcription factor activation, mediator release, inflammation and apoptosis, and COPD.

Exposures other than cigarette smoking and oxidative stress
Exposures other than cigarette smoking can impact the risk for COPD. Almost all of these exposures are particle related. Such exposures can include environmental tobacco smoke, burning of biomass, and air pollution particles. All these particle exposures, environmental and occupational, can result in oxidative stress. Production of ROS results either directly from the particle supporting an inappropriate electron transfer or from an interaction of the particle with cell proteins (e.g., electron transport complexes in the mitochondria). Oxidative stress is accepted as the initial step in the biological effect after particle exposures. In vitro exposures of cells to particles result in oxidant generation in a wide range of cell types, including phagocytic, epithelial, and endothelial cells. In vivo oxidative production following exposure to different particles has also been confirmed. Oxidant production by these particles initiates a pathway of cell signaling, activation of transcription factors, and release of mediators, and culminates in an inflammatory lung injury.

Oxidative stress and mucin gene expression in COPD and CB
COPD is one of the most common respiratory diseases worldwide. This disease is defined by the presence of an irreversible airflow obstruction and is characterized by the
presence of both oxidative stress and airway inflammation. The disease encompasses several phenotypes: emphysema, small airway obstruction and obliteration, and CB. A majority of patients with COPD have CB, and this diagnosis is associated with a higher risk for respiratory-related death. CB is diagnosed in patients with a productive chronic cough for at least 3 months per year for 2 consecutive years. Patients with CB have a greater risk of COPD exacerbations and more respiratory symptoms due to mucus obstruction of airways and secondary bacterial and viral bronchitis. Airway mucus obstruction in CB is due to several potential factors: 1) ciliated cells are injured by proteases and by oxidative injury, resulting in failure of the mucociliary escalator; 2) there is increased production and secretion of the major macromolecular constituent of mucus, namely, mucin glycoproteins; specifically, two respiratory tract gel-forming mucins, MUC5AC and MUC5B, are increased in the airway mucus and associated with hypertrophy and hyperplasia of mucus cells in the submucosal glands and superficial airway epithelium; 3) the airway mucus is dehydrated due to tobacco smoke-triggered downregulation of the cell surface expression of the cystic fibrosis transmembrane conductance regulator; and 4) the presence of plasma proteins, glycosaminoglycans and proteoglycans, DNA, lipids, and inflammatory cells and pathogens in CB airway mucus that change the normal biophysical properties of mucus (reviewed in Fahy and Dickey).

Oxidative stress, generated by tobacco smoke and augmented by ROS generated from both inflammatory cells and mitochondrial activity by cells resident in the respiratory tract, regulate mucin gene expression and mucous cell metaplasia. Tobacco smoke upregulates MUC5AC expression via epidermal growth factor receptor (EGFR)-dependent and -independent activation of activator protein 1 (AP-1), or via specificity protein 1 (Sp1) activation. Tobacco smoke also upregulates IL-8, which may function as an autocrine/paracrine regulator of MUC5AC. Tobacco smoke constituents, including aldehydes (eg, acrolein) and H₂O₂, also upregulate mucin gene expression. Acrolein-induced mucin production is mediated by matrix metalloproteinase (MMP) and by MMP14, and monoocyte-dominant inflammation augments acrolein-induced upregulation of MUC5AC. Similarly, H₂O₂ exposure upregulates MUC5AC mRNA expression by an NADPH oxidoreductase 4 (NOX4)-dependent mechanism. Smoking will trigger the influx of neutrophils into the airways and release of neutrophil elastase (NE) into the airways. We have reported that NE regulates MUC5AC gene expression via a mechanism dependent on ROS and catalyzed by NADPH quinone oxidoreductase 1 (NQO1) activity. In addition, oxidant-generated hyaluronan fragments upregulate both MUC5AC and MUC5B in airway epithelial cells. Importantly, tobacco smoke also sustains goblet cell metaplasia by suppressing Bik, a proapoptotic molecule, therefore preventing apoptosis of mucous cells. Developmental determinants of goblet cell differentiation, SAM pointed domain ETS factor (Spdef) and FOXA3, are present in COPD airway epithelial cells, but the regulatory mechanisms that govern their expression are not known (reviewed in Whitsell et al).

Interestingly, several components of the Notch signaling pathway, the receptor Notch 3 and the effectors HES5 and HEY2, are decreased in healthy smokers compared to healthy nonsmokers, suggesting that Notch suppression sustains airway mucous cell hyperplasia/hypertrrophy.

Genetic and epigenetic regulation of oxidative stress in COPD

Tobacco smoke activates lipid peroxidation and carbonyl stress (reviewed in Kirkham and Barnes), resulting in DNA damage and airway epithelial cell senescence and apoptosis (reviewed in Nyunoya et al); these are important pathways that contribute to both emphysema and airway remodeling. However, only a small portion of smokers develop COPD, emphasizing the importance of host factors in regulating tobacco smoke-induced oxidative stress and COPD. To determine the genetic factors predisposing to COPD, several approaches have been applied. Some investigators have focused on the transcriptional and epigenetic regulation of specific molecular and cellular pathways relevant to emphysema and CB phenotypes. In contrast, other investigators have leveraged consortia of large patient cohorts to interrogate unbiased genome-wide associations and discover single nucleotide polymorphisms (SNPs) that correlate with disease.

Using airway epithelial cells obtained by bronchoscopies from a large cohort of patients with and without COPD and segregated for pulmonary function test severity, signatures of gene expression have been identified by microarray in airway epithelia that are consistent with the gene expression data from lung tissues in patients with emphysema. The expression of at least two oxidant-regulated genes are increased in COPD and include CYP2C18, a P450 enzyme, and aryl hydrocarbon receptor nuclear translocator-like 2 (ARNTL2), a basic helix-loop-helix transcription factor that is active under conditions of low oxygen tension.

Using a candidate gene approach, several genetic mutations in antioxidant genes are linked to COPD severity (reviewed in). Polymorphisms in glutathione S-transferase...
expression levels of identified genes in tissues (eQTL) which genes specific to ethnic backgrounds, using too broad a phenotype. Other challenges for GWAS analysis include potentially missing modifying factors, was identified as a COPD susceptibility gene at the level of significance in these studies. Using a consortia of large COPD cohorts that included the COPDGene study (non-Hispanic white and African-American ethnic origin) and the ECLIPSE, NETT/NAS, and Norway GenKOLS studies, 6,633 individuals with moderate-to-severe COPD and 5,704 control individuals were evaluated, and three known COPD GWAS gene candidates were identified: CHRNA3, FAM13A, and HHIP. In addition, three new associations were identified: Ras interacting/interference 3 (RIN3), MMP12, and TGFβ2. As phenotypes were characterized in detail and compared, new genome-wide associations for COPD became apparent. In one study, GWAS was conducted for a phenotype of emphysema defined by chest computed tomography scans in over 2,000 individuals with COPD. This analysis detected a near-significant association between the genomic region encompassing bicaudal D homolog 1 (BCD1) and emphysema severity. BCD1 is associated with dynein function and telomere shortening. Another study evaluated computed tomography scan severity of emphysema across ethnic groups and determined the following GWAS related to ethnic background: small nuclear ribonucleoprotein (GST) M1, GSTP1, superoxide dismutase 3 (SOD3), and microsomal epoxide hydrolase (EPHX1) are associated with more rapid decline in lung function in COPD.

Epigenetic regulatory pathways are also activated by oxidative stress. The effect of miRNAs on signaling pathways in COPD varies with biospecimen source and the mechanism of miRNA regulation. A good example of this complexity is the biology of miR-199a-5p in COPD. One report demonstrates that increased expression of miR-199a-5p in the lung tissue of COPD patients correlates with downregulation of hypoxia inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF); this function of miR-199a-5p is demonstrated in human endothelial cells in vitro.97 Another recent report demonstrates that promoter methylation of miR-199a-5p in monocytes occurs in α1-antitrypsin (A1AT) ZZ symptomatic patients, resulting in suppression of miR-199a-5p expression and subsequent upregulation of the unfolded protein response.98 Both pathways engaging miR-199a-5p result in emphysema, but by very different mechanisms.

Methylation of DNA CpG islands is broadly increased both in blood leukocytes and in small airway epithelia of COPD patients. The genes targeted by differential methylation in the small airways downregulate Nrf2 expression, resulting in loss of phase II metabolizing enzymes that provide antioxidant protection.100 Tobacco smoke downregulates histone deacetylases (HDACs), resulting in increased oxidation and protease activity. HDAC2 is decreased in COPD macrophages and lung tissues, and this is associated with increased H4 acetylation localized to the promoter of IL-8.101 HDAC2 downregulation impairs Nrf2 activation in the lung by decreasing the half-life of Nrf2.102 Sirtuin1 (SIRT1), a type III HDAC, is redox sensitive and can be post-translationally modified, leading to proteosomal degradation. Loss of SIRT1 correlates with tissue inhibitor of metalloproteinase (TIMP)-1 lysine acetylation and subsequent degradation of TIMP-1, the major anti-MMP protease, resulting in increased MMP-9 in human COPD lung tissue.103 Genome-wide association studies (GWAS) have identified a few SNPs associated with COPD, but the frequency of these polymorphisms in the population do not explain the much larger frequency of disease occurrence, suggesting that environmental exposures and/or epigenetic regulation have a significantly greater impact on phenotype. Other challenges for GWAS analysis include potentially missing modifying genes that interact with GWAS-identified genes, missing genes specific to ethnic backgrounds, using too broad a phenotype to test associations, and not considering the impact of expression levels of identified genes in tissues (eQTL) which would strengthen the association of genetic polymorphisms to phenotype.104 Two studies evaluated thousands of subjects phenotyped by the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria for severity of COPD. The studies compared smokers with airflow obstruction to smokers with no airflow obstruction. Both studies detected significant levels of expression of SNPs on chromosome (chr) 15 spanning several genes including nicotinic acetylcholine receptors 3–5 (CHRNA3–5), and iron response element binding protein 2.105,106 One study identified family with sequence similarity 13 member A (FAM13A) on chromosome (chr) 4, a Rho A inhibitor, important for regulating oxidative stress and apoptosis in COPD lung cells. The following chromosomal localizations and gene candidates were determined to be related to forced expiratory volume in 1 second (FEV1): chr 4q24, glutathione S-transferase, C-terminal containing domain (GSTCD); chr 2q35, tensin 1 (TNS1); and chr 5q33, 5-hydroxytryptamine (serotonin) receptor 4 (HTR4). Similarly, for a decreased FEV1/forced vital capacity ratio, the following chromosomes and associated gene candidates were identified: chr 6p21, advanced glycosylation end product-specific receptor (AGER); and chr 15q23, thrombospondin, type I, domain containing 4 (THSD4).107 Finally, hedgehog interacting protein (HHIP), a developmental transcription factor, was identified as a COPD susceptibility gene at the level of significance in these studies. Using a consortia of large COPD cohorts that included the COPDGene study (non-Hispanic white and African-American ethnic origin) and the ECLIPSE, NETT/NAS, and Norway GenKOLS studies, 6,633 individuals with moderate-to-severe COPD and 5,704 control individuals were evaluated, and three known COPD GWAS gene candidates were identified: CHRNA3, FAM13A, and HHIP. In addition, three new associations were identified: Ras interacting/interference 3 (RIN3), MMP12, and TGFβ2.108 As phenotypes were characterized in detail and compared, new genome-wide associations for COPD became apparent. In one study, GWAS was conducted for a phenotype of emphysema defined by chest computed tomography scans in over 2,000 individuals with COPD. This analysis detected a near-significant association between the genomic region encompassing bicaudal D homolog 1 (BCD1) and emphysema severity. BCD1 is associated with dynein function and telomere shortening. Another study evaluated computed tomography scan severity of emphysema across ethnic groups and determined the following GWAS related to ethnic background: small nuclear ribonucleoprotein
polypeptide F (SNRPF) and palmitoyl protein thioesterase 2 (PPT2) in non-Hispanic whites; for Hispanic subjects, α-mannosidase-related gene (MAN2B1); for Chinese subjects, DEAH box helicase 15 (DHX15) and mannosyl–glucosaminyl transferase 5B (MGAT5B), which acts on α-linked mannose; and, for African Americans, a third α-mannosidase-related gene, MAN1C1. The relation of GWAS to oxyhemoglobin saturations in two large cohorts, COPDGene and ECLIPSE, was tested. African Americans in COPDGene had SNP associations on chr 14 and 15. Candidate genes include forkhead box G1 (FOXG1) on chr 14, and, on chr 15, candidate genes include DNA topoisomerase-2-binding protein 1 (TOPBP1)-interacting checkpoint and replication regulator (TICRR), a regulator of cell cycle progression, and kinesin family member 7 (KIF7), a regulator of sonic hedgehog signaling. Chr 15 had no associations with COPD in non-Hispanic whites. GWAS for chronic mucus hypersecretion was associated with special AT-rich sequence-binding protein 1 locus (SATB1) on chr 3. This gene regulates chromatin structure. Although the original correlation was less than usually accepted for statistical correlation, the GWAS SNP was independently verified in other large COPD GWAS cohorts, and there was eQTL evidence of increased expression of SATB1 mRNA in tissues of patients with chronic mucus hypersecretion.

Tremendous progress has been made in identifying environmental and inherited risk factors for COPD and CB. There are several target genes that increase susceptibility to COPD via oxidant-mediated pathways. Moreover, oxidant signaling pathways play a major role in airway remodeling relevant to CB. The next frontier to understanding how inheritance increases the risk of COPD disease susceptibility will be investigation of the early origins of COPD in childhood and infancy, including consideration of the role of inherited epigenetic factors. Factors that reduce ultimate lung growth or antioxidant capacity may be discovered, leading to new approaches to prevention or treatment of COPD.

### Current and emerging antioxidants, diet, and alternative therapies

Studies have been undertaken to evaluate the clinical effectiveness of antioxidant therapy for COPD. Potential antioxidant therapies were reviewed in 2008, and again in 2013, with both reports suggesting that certain classes of antioxidants be evaluated for the clinical usefulness in COPD, including: thiol compounds (eg, NAC, carbocysteine), Nrf2 activators (eg, sulforaphane), antioxidant vitamins (eg, vitamin E and C), and food/diet-derived polyphenols (eg, curcumin and resveratrol) (see Table 1). Some of these antioxidants have been evaluated in rodent and/or human studies. For example, in one study, carbocysteine, a thiol antioxidant, was evaluated for its impact on COPD exacerbation rate in a randomized, placebo-controlled trial. In the Chinese COPD patients evaluated, the investigators reported that carbocysteine was well tolerated, and that it significantly decreased exacerbation rate over a 1-year period. Similarly, in a more recent randomized, placebo-controlled study with stable COPD patients in Hong Kong, 1-year treatment with high-dose NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, was evaluated for its impact on COPD exacerbation rate in a randomized, placebo-controlled trial. Studies have been undertaken to evaluate the clinical effectiveness of antioxidant therapy for COPD. Potential antioxidant therapies were reviewed in 2008, and again in 2013, with both reports suggesting that certain classes of antioxidants be evaluated for the clinical usefulness in COPD, including: thiol compounds (eg, NAC, carbocysteine), Nrf2 activators (eg, sulforaphane), antioxidant vitamins (eg, vitamin E and C), and food/diet-derived polyphenols (eg, curcumin and resveratrol) (see Table 1). Some of these antioxidants have been evaluated in rodent and/or human studies. For example, in one study, carbocysteine, a thiol antioxidant, was evaluated for its impact on COPD exacerbation rate in a randomized, placebo-controlled trial. In the Chinese COPD patients evaluated, the investigators reported that carbocysteine was well tolerated, and that it significantly decreased exacerbation rate over a 1-year period. Similarly, in a more recent randomized, placebo-controlled study with stable COPD patients in Hong Kong, 1-year treatment with high-dose NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency. This group also reported an improvement in the forced expiratory flow 25%–75% by 16 weeks of NAC therapy, another thiol antioxidant, also reduced exacerbation frequency.

### Table 1 Clinical application of antioxidants summary table

<table>
<thead>
<tr>
<th>Class of antioxidants</th>
<th>Examples</th>
<th>Clinical application (RCT or other)</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiols</td>
<td>N-acetylcysteine, carbocysteine</td>
<td>Decreased COPD exacerbation rate (RCT).</td>
<td>117,118</td>
</tr>
<tr>
<td>Nrf2 activators</td>
<td>Sulforaphane</td>
<td>No RCTs yet. Ex vivo/in vitro study demonstrates improved glucocorticoid sensitivity in alveolar macrophages from COPD patients.</td>
<td>102</td>
</tr>
<tr>
<td>Food/plant-derived polyphenols</td>
<td>Curcumin, resveratrol</td>
<td>No RCTs yet. Oral curcumin in a mouse model of emphysema attenuated lung lavage neutrophils and mean linear intercept measurements.</td>
<td>123</td>
</tr>
<tr>
<td>Dietary modifications</td>
<td>Increased fruit and vegetable intake</td>
<td>Large population review studies demonstrated positive association with FEV1 with increased flavonoid intake (solid fruits) and decreased COPD-associated mortality risk in men. A single RCT over a 3-year period with increased fruit and vegetable intake demonstrated increased FEV1 (% predicted) and decreased exacerbation rate.</td>
<td>127–129,133</td>
</tr>
<tr>
<td>Vitamins</td>
<td>Vitamins C, E, and D</td>
<td>Important to address deficiencies. Insufficient data to suggest high-dose supplementation to temper respiratory pathology. Often used in combination with other nutrient supplements, herbs, or diet modifications.</td>
<td>126,128,142–144</td>
</tr>
</tbody>
</table>

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; Nrf2, nuclear factor erythroid 2-related factor 2; RCT, randomized controlled trial.
therapy on lung function. The exact mechanism of action of NAC regulation of exacerbation frequency is not clear. Tse et al propose that it is the antioxidant and anti-inflammatory properties of NAC; however, one report suggests that it may also be that NAC helps restore the normal antiviral innate immune response that is suppressed by cigarette smoking.\textsuperscript{119} Thiol antioxidants show promise as one component of the COPD therapeutic “toolbox”, with their ability to attenuate exacerbation frequency, which may potentially help slow disease progression.

Nrf2 plays an important role in protection against ROS, especially those triggered by smoking. Nrf2 is a transcription factor which can bind to the antioxidant response element of important stress response genes. It regulates many of the antioxidant and phase II cytoprotective genes. Nrf2 and its importance in COPD pathophysiology has been studied in rodent models and with cells from COPD patients. Sulforaphane, derived from broccoli sprouts, is an Nrf2 activator that is being considered for potential clinical trials in COPD. Sulforaphane has been evaluated in ex vivo/in vitro studies. In one study using alveolar macrophages from COPD patients, sulforaphane treatment helped restore glucocorticoid sensitivity, through a glutathione-dependent mechanism, to increase HDAC2 activity.\textsuperscript{102} Food/plant-derived polyphenols, such as curcumin and resveratrol, have also been evaluated in a similar ex vivo/in vitro manner. Curcumin, the active constituent from turmeric, has anticancer and anti-inflammatory properties.\textsuperscript{120,121} Similar to sulforaphane, curcumin treatment of a monocytic cell line reversed cigarette smoke extract- or peroxide-induced steroid resistance by restoring HDAC2 activity and expression.\textsuperscript{122} In a mouse model of cigarette smoke-induced emphysema, oral curcumin therapy significantly attenuated lung lavage neutrophils and macrophages as well as lung mean linear intercepts as a measure of emphysema.\textsuperscript{123} Resveratrol, another polyphenolic compound that is derived from red wine, also has antioxidant and anti-inflammatory properties.\textsuperscript{115,124} Resveratrol treatment of alveolar macrophages from COPD patients significantly reduced bacterial endotoxin-induced cytokine production despite steroid insensitivity.\textsuperscript{125}

Dietary modification may be another avenue of promising intervention for COPD patients.\textsuperscript{126} Two studies from the Netherlands suggest that diets rich in solid fruits may be beneficial in limiting COPD symptoms and/or mortality.\textsuperscript{127,128} The first study, by Tabak et al, focused on dietary intake of polyphenolic bioflavonoids and measured three subclasses: catechins, flavonols, and flavones. Total flavonoid intake was positively associated with FEV\textsubscript{1} and inversely associated with cough and breathlessness.\textsuperscript{127} The second study, by Walda et al, also included patients from European countries and evaluated the 20-year mortality rate in men. Increased dietary intake of fruit and vitamin E demonstrated an inverse trend in 20-year COPD mortality with a corresponding 24% lower COPD mortality risk.\textsuperscript{128} In a follow-up to the Tabak et al study,\textsuperscript{127} a 5-year follow-up was performed and a subset of these patients with valid initial study lung function measurements were included in a study to evaluate the relationship of dietary intake to FEV\textsubscript{1} decline over time. McKeever et al reported that people eating a more traditional diet, with intake of meat and potatoes dominating, was associated with a lower FEV\textsubscript{1} and an increased incidence of COPD.\textsuperscript{129} These two studies focused on solid fruits, in particular apples and pears, but other fruits are rich in polyphenols and bioflavonoids. Guava is one fruit whose extract is very phenolic rich; it has been proposed as potential COPD therapy, but not yet evaluated in clinical trials.\textsuperscript{130} Blueberries are another antioxidant bioflavonoid-rich food. In healthy men, blueberry intake has been shown to improve vascular function.\textsuperscript{131} Two dietary-intervention randomized controlled trials reported differing results. One study, based in the United Kingdom, had patients increase fruit and vegetable intake to at least five servings per day, while the control group consumed two or less portions per day for 12 weeks.\textsuperscript{132} Over this short period, there were no changes in lung function nor in markers of either oxidative stress or inflammation.\textsuperscript{132} However, a study in Greece, in which the intervention group increased their fruit and vegetable consumption over a 3-year period, demonstrated a significant increase in FEV\textsubscript{1} (% predicted) over time.\textsuperscript{133} Furthermore, the intervention group also demonstrated a significant decrease in the mean annual exacerbation rate.\textsuperscript{133} In addition, recent reports also highlight the importance of overall nutritional support, improved dietary quality, and increased dietary fiber for COPD management.\textsuperscript{134–136} Collectively, these studies suggest a diet rich in fruits providing polyphenolic bioflavonoids and other antioxidants (eg, proanthocyanidins\textsuperscript{137}) along with dietary advice\textsuperscript{138} as important for the overall management of COPD.

Vitamins are generally obtained from our diets; however, is vitamin supplementation helpful for COPD management? Schols, in a recent translational paper,\textsuperscript{126} felt that there is insufficient evidence to support taking high doses of single nutrient supplements to temper respiratory pathology; however, addressing vitamin deficiencies may be considered. It is important to note that caution must be used when using high-dose vitamin supplementation. There have been reports that, for some vitamins (eg, vitamin A),
high-dose supplementation can increase the risk of lung cancer and mortality in susceptible individuals. In an ex vivo/in vitro analysis, compared to placebo-treated patients, white blood cells from stable COPD patients who had been supplemented with vitamin E or C for 12 weeks had increased resistance to peroxide-induced DNA breakages. In a different controlled study, ascorbate intravenous infusion improved skeletal muscle fatigue resistance in COPD patients. The combination treatment of vitamin C, zinc, selenium, and Echinacea purpurea, a herb that has been used for treating the common cold, helped shorten COPD exacerbation episodes.

Many people have studied the relationship of vitamin D with COPD management with varying results. A summary of the information from several reports, listed in chronological order, is shown in Table 2. Collectively, these studies suggest that COPD patients with serum 25-hydroxyvitamin D (25-OH vitamin D) below 20 ng/mL are deficient and may be at increased risk of exacerbations, worse lung function, and decline in lung function with time. This concept is supported in a review about vitamin insufficiencies and supplementation for COPD, in which Tsiligianni and van der Molen point out that the majority of COPD patients have vitamin D deficiency and that supplementation might perhaps be beneficial. Lehouck et al suggest that it is generally only the COPD patients with severe deficiencies of serum 25-OH vitamin D <10 ng/mL who may benefit from vitamin D supplementation. Vitamin D is important as an immune system regulator and, given that low serum 25-OH vitamin D levels have been associated with many chronic diseases (eg, autoimmune disease, cardiovascular disease, and infections), vitamin D supplementation may be an important therapeutic strategy for COPD that is worthy of further investigation.

Therapeutic strategies that can attenuate the inflammatory response can, in turn, attenuate oxidative stress. Alternative therapies such as herbal preparations, acupuncture, and tai chi or qigong may each help mitigate the overall inflammatory status of the COPD patient, either directly or indirectly. In the past few years, there have been multiple systematic reviews published relating to herbal therapies for COPD. One of these reports focused specifically on the combination of Tanreqing injection along with conventional therapy. Tanreqing is a standardized herbal formula administered by intravenous drip, which has been shown to have some antibacterial and antiviral effects along with anti-inflammatory actions. Tanreqing combined with conventional therapies demonstrated improvements in lung function and oxygenation, as well as decreased length of hospital stays, with no serious adverse events reported. Ginseng is a single herbal product that has also been evaluated for use with COPD patients. It is known for supporting qi of the lung and spleen to improve the functions of these organs and has been used for respiratory diseases. Studies were performed in a similar manner to that involving Tanreqing with ginseng given in combination with other therapies. As with Tanreqing, systematic review of the ginseng studies reported improvements in lung function and quality of life (Qol) scores based on the St George’s Respiratory Questionnaire (SGRQ). Other studies have also focused on herbal therapies for improvement of Qol for COPD patients. Based on systematic review of the literature, oral Chinese herbal medicines resulted in improvement in Qol scores when compared to no treatment or routine therapies. A recent systematic review addressed the impact of Chinese herbal medicines on the body mass index, airflow obstruction, dyspnea, and exercise (BODE) index and the 6-minute walk test (6MWT). The 6MWT provides the exercise capacity score for the BODE index, while the BODE index correlates well overall with COPD mortality. Results from the systematic review suggest a benefit for the BODE index and the 6MWT by the combination of Chinese herbal medicine with routine therapies, suggesting an overall clinical benefit, too. The main herbs used for the studies were Astragalus membranaceus, Panax ginseng, and Cordyceps sinensis alone or, sometimes, in combination with other herbs. Collectively, these systematic reviews suggest a benefit of Chinese medicine herbal preparations for treatment of specific aspects of the overall COPD disease complex and that further large-scale high quality studies are warranted.

Acupuncture is another Chinese modality that has been evaluated as adjunctive therapy for COPD patients. Acupuncture can be administered in different ways and may be different for each patient. To control for these types of variability, Suzuki et al, in their studies, standardized the acupuncture treatment protocol and used the same acupuncture points for all patients. In a small study, all patients received conservative treatment and one-half also received acupuncture for 10 weeks. The control group was matched to the treatment group but did not receive any sham treatment. The patients receiving acupuncture showed improvement in the modified Borg dyspnea scale and in oxygen saturation during the 6MWT. The next study by the same group was also a small trial, which showed similar improvements after 10 weeks of acupuncture. Suzuki et al then performed a slightly larger trial, now placebo-controlled, that extended the acupuncture to 12 weeks and included eleven different acupuncture points similar to those used in previous studies.
<table>
<thead>
<tr>
<th>Year of publication</th>
<th>Article title or study goal</th>
<th>Population studied and type of study</th>
<th>Results of the study</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>Relationship of vitamin D and URTI.</td>
<td>USA; observational cohort study.</td>
<td>Serum 25-OH vitamin D was inversely associated with recent URTI. Participants with serum 25-OH vitamin D &lt; 10 ng/mL had more recent URTI than participants with levels ≥30 ng/mL. Total vitamin D intake (diet and supplements) was positively associated with serum 25-OH vitamin D, but was positively associated with COPD prevalence.</td>
</tr>
<tr>
<td>2011</td>
<td>Relationship of vitamin D status to adult lung function and COPD</td>
<td>Hertfordshire Cohort Study, UK; observational cohort study.</td>
<td>Total vitamin D intake (diet and supplemental) was positively associated with FEV1, FEV1/FVC ratio and decreasing odds of COPD prevalence. However, serum 25-OH vitamin D was not associated with FEV1, but was positively associated with COPD prevalence.</td>
</tr>
<tr>
<td>2012</td>
<td>High doses of vitamin D to reduce COPD exacerbations – randomized trial.</td>
<td>Leuven, Belgium; randomized, single-center, double-blind, placebo-controlled trial.</td>
<td>Treatment: 100,000 IU of vitamin D or placebo every 4 weeks for 1 year. Among the total 182 patients studied, no significant differences were noted. However, those patients with severe vitamin D deficiency (serum 25-OH vitamin D &lt; 10 ng/mL) at baseline who received the vitamin D supplementation had a significant decrease in their exacerbation rate.</td>
</tr>
<tr>
<td>2012</td>
<td>Relationship of vitamin D deficiency (serum 25-OH vitamin D &lt; 20 ng/mL) with smoking and lung function.</td>
<td>Dutch and Swiss primary care settings; 365 patients; prospective cohort study.</td>
<td>In the overall cohort, there were no direct associations between vitamin D deficiency and smoking and lung function. However, current smokers with vitamin D deficiency had corresponding lower lung function and more rapid decline of FEV1 per pack-year of smoking.</td>
</tr>
<tr>
<td>2014</td>
<td>No association of 25-OH vitamin D with COPD exacerbations</td>
<td>VA Normative Aging Study (only men in this cohort).</td>
<td>No significant associations, but a trend for lower risk of exacerbation was found in patients with sufficient levels. All patients with levels ≥30 ng/mL had equivalent risk of exacerbation.</td>
</tr>
</tbody>
</table>

Abbreviations: 25-OH, 25-hydroxyvitamin D; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in second; FVC, forced vital capacity; URTI, upper respiratory tract infection; VA, Department of Veterans Affairs.
Similar results were reported in this controlled trial, with improvement in the Borg scale score in the acupuncture-treated patients. The reports from Suzuki et al were without electrical stimulation through the acupuncture needles. Studies were also performed using Acu-TENS, which is transcutaneous electrical nerve stimulation on acupuncture point sites. One study was a double-blinded, randomized controlled trial with Acu-TENS or placebo-TENS on a single acupuncture point site, once for 45 minutes. FEV₁ improved in the Acu-TENS-treated patients immediately posttreatment. There was also a corresponding increase in blood β-endorphin levels. In a subsequent study, which was also a randomized controlled trial, the patients received 4 weeks of Acu-TENS treatment. This study had both placebo-TENS and sham-TENs control groups. Placebo is where the TENS stimulation electrodes are placed on the patient over the appropriate acupuncture point but without electrical stimulation applied. For the sham treatment group, electrical stimulation is applied to another part of the body that is a non-acupuncture point. Similarly to the previously mentioned study, Ngai et al demonstrated improvement in FEV₁. They also demonstrated improvements in oxygen saturation and distance for the 6MWT and improvement in the SGRQ Qol score, with corresponding increases in blood β-endorphin levels. Collectively, these studies suggest that acupuncture with or without electrical stimulation promotes improved oxygenation in COPD patients.

Tai chi and qigong (TCQ) are traditional Chinese exercises with emphasis on specific focused movements, meditation, and breathing exercises. In a qigong randomized controlled study presented as a mind–body exercise intervention, the patients participating in the qigong exercises demonstrated significant improvement on the monitored functional task evaluation and the 6MWT by the 6-month follow-up. In a separate randomized controlled trial, TCQ were compared to other breathing and self-paced walking exercises or normal routine (ie, no extra exercise), demonstrating, by the end of the 3-month treatment period, improved lung function and 6MWT and decreased exacerbation rate in the TCQ group compared to the two other groups. In a systematic review of TCQ COPD trials, compared to no exercise, TCQ therapy promoted significant improvements in 6MWT, FEV₁, and FEV₁% predicted as well as SGRQ Qol score; however, compared to other exercise training, there was only improvement in the 6MWT. Similar to acupuncture, TCQ is an alternative therapy that shows potential benefit for COPD patients and is worthy of further investigation with high-quality trials. It is important to note that the placebo effect does not improve physiologic measures, but is associated with significant improvement in well-being as measured by surveys. Thus, the randomized, placebo-controlled trials show that complementary medicines do have a significant physiologic effect on pulmonary function outcomes in COPD.

COPD is a complex disease process and no single treatment can treat the whole disease. Clearly, from the different studies discussed, antioxidant supplementation, dietary antioxidants, Chinese herbal preparations, acupuncture, and TCQ may each have their place in COPD therapy, necessitating the use of combination and complementary therapies. One area that has not been addressed but is worth mentioning is the microbiome. The intestinal microbiome is critical to the regulation of our immune system, and alterations in the intestinal microbiome and dysbiosis may be a component of the pathogenesis of many diseases. Furthermore, our diets can be a major influence on the intestinal microbial composition, potentially impacting our health. One study in rats demonstrated that a diet rich in blueberries promoted gut health, evaluated by colonic metabolism measurements, and minimized invasive bacterial species. Similarly, modification to a Paleolithic hunter-gatherer-type diet might be worth considering. This type of diet promotes fruit and vegetables and eliminates cereal grains, legumes, and dairy, and has been shown to promote metabolic and physiologic improvements in sedentary adults. Serial analyses of gut and respiratory microbiomes in infants with cystic fibrosis have shown that nutritional factors and gut microbial colonization patterns are determinants of respiratory tract microbial development, suggesting that dietary alterations and probiotic strategies may provide early intervention opportunities. Similar considerations are worth investigating as potential early intervention opportunities for control of COPD progression.

Disclosure
The authors report no conflicts of interest in this work.

References
272


